|
1
|
Zibrak JD and Price D: Interstitial lung
disease: Raising the index of suspicion in primary care. NPJ Prim
Care Respir Med. 24:140542014.PubMed/NCBI
|
|
2
|
Raghu G, Weycker D, Edelsberg J, Bradford
WZ and Oster G: Incidence and prevalence of idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med. 174:810–816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esposito DB, Lanes S, Donneyong M, Holick
CN, Lasky JA, Lederer D, Nathan SD, O'Quinn S, Parker J and Tran
TN: Idiopathic pulmonary fibrosis in US automated claims:
Incidence, prevalence and algorithm validation. Am J Respir Crit
Care Med. 192:1200–1207. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Azuma A: Pirfenidone: Antifibrotic agent
for idiopathic pulmonary fibrosis. Expert Rev Respir Med.
4:301–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rancoule C, Pradère JP, Gonzalez J, Klein
J, Valet P, Bascands JL, Schanstra JP and Saulnier-Blache JS:
Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
Expert Opin Investig Drugs. 20:657–667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang LS and Natarajan V: Sphingolipids in
pulmonary fibrosis. Adv Biol Regul. 57:55–63. 2015. View Article : Google Scholar :
|
|
7
|
Wynn TA: Integrating mechanisms of
pulmonary fibrosis. J Exp Med. 208:1339–1350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shashidharamurthy R, Koteiche HA, Dong J
and McHaourab HS: Mechanism of chaperone function in small heat
shock proteins: Dissociation of the HSP27 oligomer is required for
recognition and binding of destabilized T4 lysozyme. J Biol Chem.
280:5281–5289. 2005. View Article : Google Scholar
|
|
9
|
Hadaschik BA, Jackson J, Fazli L, Zoubeidi
A, Burt HM, Gleave ME and So AI: Intravesically administered
antisense oligonucleotides targeting heat-shock protein-27 inhibit
the growth of non-muscle-invasive bladder cancer. BJU Int.
102:610–616. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamada M, So A, Muramaki M, Rocchi P,
Beraldi E and Gleave M: Hsp27 knockdown using nucleotide-based
therapies inhibit tumor growth and enhance chemotherapy in human
bladder cancer cells. Mol Cancer Ther. 6:299–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wettstein G, Bellaye PS, Kolb M, Hammann
A, Crestani B, Soler P, Marchal-Somme J, Hazoume A, Gauldie J,
Gunther A, et al: Inhibition of HSP27 blocks fibrosis development
and EMT features by promoting Snail degradation. FASEB J.
27:1549–1560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Della Latta V, Cecchettini A, Del Ry S and
Morales MA: Bleomycin in the setting of lung fibrosis induction:
From biological mechanisms to counteractions. Pharmacol Res.
97:122–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wolters PJ, Collard HR and Jones KD:
Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol.
9:157–179. 2014. View Article : Google Scholar :
|
|
14
|
Huang LS, Fu P, Patel P, Harijith A, Sun
T, Zhao Y, Garcia JG, Chun J and Natarajan V: Lysophosphatidic acid
receptor-2 deficiency confers protection against bleomycin-induced
lung injury and fibrosis in mice. Am J Respir Cell Mol Biol.
49:912–922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang LS, Berdyshev E, Mathew B, Fu P,
Gorshkova IA, He D, Ma W, Noth I, Ma SF, Pendyala S, et al:
Targeting sphingosine kinase 1 attenuates bleomycin-induced
pulmonary fibrosis. FASEB J. 27:1749–1760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun X, Chen E, Dong R, Chen W and Hu Y:
Nuclear factor (NF)-κB p65 regulates differentiation of human and
mouse lung fibroblasts mediated by TGF-β. Life Sci. 122:8–14. 2015.
View Article : Google Scholar
|
|
17
|
Huang LS, Mathew B, Li H, Zhao Y, Ma SF,
Noth I, Reddy SP, Harijith A, Usatyuk PV, Berdyshev EV, et al: The
mitochondrial cardiolipin remodeling enzyme lysocardiolipin
acyltransferase is a novel target in pulmonary fibrosis. Am J
Respir Crit Care Med. 189:1402–1415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Usatyuk PV, Burns M, Mohan V, Pendyala S,
He D, Ebenezer DL, Harijith A, Fu P, Huang LS, Bear JE, et al:
Coronin 1B regulates S1P-induced human lung endothelial cell
chemotaxis: Role of PLD2, protein kinase C and Rac1 signal
transduction. PLoS One. 8:e630072013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang LS, Kim MR and Sok D-E: Enzymatic
reduction of polyunsaturated lysophosphatidylcholine hydroperoxides
by glutathione peroxidase-1. Eur J Lipid Sci Technol. 111:584–592.
2009. View Article : Google Scholar
|
|
20
|
Huang LS, Hung ND, Sok DE and Kim MR:
Lysophosphatidylcholine containing docosahexaenoic acid at the sn-1
position is anti-inflammatory. Lipids. 45:225–236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Midgley AC, Rogers M, Hallett MB, Clayton
A, Bowen T, Phillips AO and Steadman R: Transforming growth
factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast
differentiation is mediated by hyaluronan (HA)-facilitated
epidermal growth factor receptor (EGFR) and CD44 co-localization in
lipid rafts. J Biol Chem. 288:14824–14838. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morell F: Idiopathic pulmonary fibrosis:
Importance of accurate diagnosis and treatment. Arch Bronconeumol.
49:319–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Antoniou KM, Tomassetti S, Tsitoura E and
Vancheri C: Idiopathic pulmonary fibrosis and lung cancer: A
clinical and pathogenesis update. Curr Opin Pulm Med. 21:626–633.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aravena C, Labarca G, Venegas C, Arenas A
and Rada G: Pirfenidone for idiopathic pulmonary fibrosis: A
systematic review and meta-analysis. PLoS One. 10:e01361602015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hisatomi K, Mukae H, Sakamoto N, Ishimatsu
Y, Kakugawa T, Hara S, Fujita H, Nakamichi S, Oku H, Urata Y, et
al: Pirfenidone inhibits TGF-β1-induced over-expression of collagen
type I and heat shock protein 47 in A549 cells. BMC Pulm Med.
12:242012. View Article : Google Scholar
|
|
26
|
Nakayama S, Mukae H, Sakamoto N, Kakugawa
T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, et al:
Pirfenidone inhibits the expression of HSP47 in
TGF-beta1-stimulated human lung fibroblasts. Life Sci. 82:210–217.
2008. View Article : Google Scholar
|
|
27
|
Kakugawa T, Mukae H, Hayashi T, Ishii H,
Abe K, Fujii T, Oku H, Miyazaki M, Kadota J and Kohno S:
Pirfenidone attenuates expression of HSP47 in murine
bleomycin-induced pulmonary fibrosis. Eur Respir J. 24:57–65. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Razzaque MS, Le VT and Taguchi T: Heat
shock protein 47 and renal fibrogenesis. Contrib Nephrol.
148:57–69. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert
SD and Kossen K: Antifibrotic activities of pirfenidone in animal
models. Eur Respir Rev. 20:85–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seifirad S, Keshavarz A, Taslimi S, Aran
S, Abbasi H and Ghaffari A: Effect of pirfenidone on pulmonary
fibrosis due to paraquat poisoning in rats. Clin Toxicol (Phila).
50:754–758. 2012. View Article : Google Scholar
|
|
31
|
Raghu G, Johnson WC, Lockhart D and Mageto
Y: Treatment of idiopathic pulmonary fibrosis with a new
antifibrotic agent, pirfenidone: Results of a prospective,
open-label phase II study. Am J Respir Crit Care Med.
159:1061–1069. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chilosi M, Poletti V, Zamò A, Lestani M,
Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, et
al: Aberrant Wnt/beta-catenin pathway activation in idiopathic
pulmonary fibrosis. Am J Pathol. 162:1495–1502. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tager AM, LaCamera P, Shea BS, Campanella
GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND,
et al: The lysophosphatidic acid receptor LPA1 links pulmonary
fibrosis to lung injury by mediating fibroblast recruitment and
vascular leak. Nat Med. 14:45–54. 2008. View Article : Google Scholar
|
|
34
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
